You have 9 free searches left this month | for more free features.

Bendamustine Hydrochloride

Showing 76 - 100 of 2,057

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Newly Diagnosed Mantle Cell Lymphoma Trial in Zhengzhou (Rituximab)

Recruiting
  • Newly Diagnosed Mantle Cell Lymphoma
  • Zhengzhou, Henan, China
    Department of Oncology, The First Affiliated Hospital of Zhengzh
Aug 17, 2022

Mantle Cell Lymphoma Trial in United States (Ofatumumab (This arm is closed), Ofatumumab + Bendamustine)

Active, not recruiting
  • Mantle Cell Lymphoma
  • Ofatumumab (This arm is closed)
  • Ofatumumab + Bendamustine
  • Basking Ridge, New Jersey
  • +5 more
Oct 1, 2021

Diffuse Large B-cell Lymphoma Trial in Worldwide (Rituximab (RTX), Tafasitamab, Bendamustine (BEN))

Active, not recruiting
  • Diffuse Large B-cell Lymphoma
  • Rituximab (RTX)
  • +2 more
  • Anaheim, California
  • +157 more
Aug 1, 2022

Diffuse, Large B-Cell, Lymphoma Trial in China (Polatuzumab Vedotin, Bendamustine, Rituximab)

Completed
  • Diffuse, Large B-Cell, Lymphoma
  • Polatuzumab Vedotin
  • +3 more
  • Beijing, China
  • +9 more
Jul 7, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Newly Diagnosed Trial in Tianjin (Zanubrutinib, Fludarabine,

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Zanubrutinib, Fludarabine, cyclophosphamide and rituximab
  • Zanubrutinib, bendamustine, rituximab
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Mar 18, 2022

Non-Hodgkin's Lymphoma Trial in United States (ABT-199, Rituximab, Bendamustine)

Completed
  • Non-Hodgkin's Lymphoma
  • La Jolla, California
  • +7 more
Jul 29, 2021

Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Mantle-Cell Trial in Providence (Rituximab, Bendamustine, Vincristine

Active, not recruiting
  • Lymphoma, Non-Hodgkin
  • +5 more
  • Providence, Rhode Island
    Rhode Island Hospital and The Miriam Hospital
Jul 19, 2021

Mantle Cell Lymphoma Trial in Saint Louis (Bendamustine, Rituximab, Acalabrutinib)

Active, not recruiting
  • Mantle Cell Lymphoma
  • Saint Louis, Missouri
    Washington University School of Medicine
Feb 2, 2022

Lymphoma, Non-Hodgkin Trial in Canada, United States (TAK-659, Bendamustine, Rituximab)

Terminated
  • Lymphoma, Non-Hodgkin
  • Tucson, Arizona
  • +12 more
Dec 7, 2021

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Worldwide (Pirtobrutinib, Bendamustine, Rituximab)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Los Angeles, California
  • +142 more
Jan 10, 2023

Lymphoma, Non-Hodgkin Trial in Worldwide (Copanlisib (BAY80-6946), Placebo, Rituximab)

Active, not recruiting
  • Lymphoma, Non-Hodgkin
  • Copanlisib (BAY80-6946)
  • +7 more
  • Chandler, Arizona
  • +199 more
Jan 31, 2023

Chronic Lymphoid Leukemia Trial in Germany (Bendamustine, Obinutuzumab, Zanubrutinib)

Recruiting
  • Chronic Lymphoid Leukemia
  • Aachen, Germany
  • +20 more
Oct 5, 2021

Non-hodgkin Lymphoma,B Cell Trial in Beijing (Azacytidine, Bendamustine and Piamprizumab)

Recruiting
  • Non-hodgkin Lymphoma,B Cell
  • Azacytidine, Bendamustine and Piamprizumab
  • Beijing, Beijing, China
  • +1 more
May 18, 2021

Mantle Cell Lymphoma Trial in Worldwide (Bendamustine, Rituximab, Ibrutinib)

Active, not recruiting
  • Mantle Cell Lymphoma
  • Tucson, Arizona
  • +201 more
Jan 27, 2023

Refractory/Relapsed Indolent Non-Hodgkin Lymphoma Trial in United States (rituximab, bendamustine, lenalidomide)

Completed
  • Refractory/Relapsed Indolent Non-Hodgkin Lymphoma
  • rituximab
  • +2 more
  • Clive, Iowa
  • +16 more
Oct 4, 2019

Lymphoma Trial in Switzerland (rituximab, bendamustine HCl, lenalidomide)

Completed
  • Lymphoma
  • rituximab
  • +2 more
  • Baden, Switzerland
  • +15 more
May 14, 2019

Prostate Carcinoma, Prostate Small Cell Neuroendocrine Carcinoma, Stage III Prostate Cancer AJCC v8 Trial in Seattle (drug,

Not yet recruiting
  • Prostate Carcinoma
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 17, 2023

Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto

Not yet recruiting
  • Multiple Sclerosis
  • +2 more
  • KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen
  • Palo Alto, California
    Stanford Multiple Sclerosis Center
Nov 13, 2023

Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma Trial in United Kingdom (Epcoritamab, Lenalidomide, Rituximab)

Not yet recruiting
  • Relapsed Follicular Lymphoma
  • Refractory Follicular Lymphoma
  • Aberdeen, United Kingdom
  • +24 more
Apr 28, 2023

Diffuse Large B Cell Lymphoma, Transformed Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma Trial (FT596, Cyclophosphamide,

Withdrawn
  • Diffuse Large B Cell Lymphoma
  • +4 more
  • (no location specified)
Jun 28, 2023

Metastatic Colorectal Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma Trial in

Not yet recruiting
  • Metastatic Colorectal Adenocarcinoma
  • +5 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Sep 12, 2023

Lymphatic Diseases Trial in Italy (Brentuximab Vedotin, Bendamustine)

Terminated
  • Lymphatic Diseases
  • Bologna, BO, Italy
  • +4 more
May 26, 2021

Relapsed Angioimmunoblastic T-Cell Lymphoma, Refractory Angioimmunoblastic T-cell Lymphoma Trial in Worldwide (Oral azacitidine,

Active, not recruiting
  • Relapsed Angioimmunoblastic T-Cell Lymphoma
  • Refractory Angioimmunoblastic T-cell Lymphoma
  • Oral azacitidine
  • +3 more
  • Graz, Austria
  • +33 more
Aug 24, 2022

Relapsed or Refractory DLBCL Trial in United States (Selinexor, Rituximab, Bendamustine)

Suspended
  • Relapsed or Refractory Diffuse Large B-Cell Lymphoma
  • Tucson, Arizona
  • +17 more
Jan 24, 2023

Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma Trial in United States (Duvelisib, Placebo,

Withdrawn
  • Indolent Non-Hodgkin's Lymphoma
  • +3 more
  • Plainville, Connecticut
  • +6 more
Mar 15, 2021